Literature DB >> 23852445

Outcomes among athletes with arrhythmias and electrocardiographic abnormalities: implications for ECG interpretation.

David McClaskey1, Daniel Lee, Eric Buch.   

Abstract

Electrocardiographic (ECG) aberrations and arrhythmias occur frequently among athletes due to normal variants, subclinical cardiac disease or structural and electrical remodeling in response to training. It is unclear whether these changes are associated with adverse clinical outcomes over time among otherwise asymptomatic, healthy athletes. Consensus guidelines have been developed to guide the clinician regarding further management of these arrhythmias. The purpose of this review is to summarize prospective data regarding cardiovascular outcomes related to ECG changes among athletes and compare these findings with current guidelines. A review of the literature was conducted using the PubMed database (1966--present). Outcomes of interest included documented cardiac symptoms or events, such as episodes of cardiac or cerebral hypoperfusion, sudden death or prophylactic procedural interventions. Studies were included for analysis if they involved (1) athletes with documented, baseline arrhythmias and/or abnormal ECG variations; (2) a study design with longitudinal follow-up (designated as >1 month, to exclude short-term Holter studies); and (3) outcomes that include documented cardiac symptoms or events. A total of 33 studies met the above criteria, encompassing over 4,200 athletes, with follow-up ranging from 2 months to 14.6 years. There were few adverse outcomes among cases of sinus bradycardia >30 bpm, sinus pauses <3 s, first-degree atrioventricular (AV) block, second-degree type I AV block and incomplete right bundle branch block. Results among these studies are concordant with guidelines that recommend work-up in the setting of cardiac symptoms, history or physical examination indicative of cardiac disease, severe sinus bradycardia or AV block that does not resolve with exercise or hyperventilation. Outcomes among prospective studies also support guidelines that recommend further evaluation for repolarization abnormalities and supraventricular tachycardias, including atrial fibrillation, atrial flutter and Wolff-Parkinson-White syndrome. Ventricular arrhythmias in the setting of structural cardiac disease are associated with an increased risk of adverse events, including sudden cardiac death, and warrant special consideration with regards to sports eligibility. Findings in this review are limited by a lack of control groups, limited assessment of confounding factors (such as performance-enhancing drugs), and under-representation of women and certain ethnicities. Further prospective studies are needed to better characterize the long-term outcome of ECG abnormalities among athletes and provide evidence for ECG interpretation guidelines.

Entities:  

Mesh:

Year:  2013        PMID: 23852445     DOI: 10.1007/s40279-013-0074-5

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  68 in total

1.  Symptomatic hypervagotonia in a highly conditioned athlete.

Authors:  Javed M Nasir; Steven J Durning; Roy L Johnson; Mark C Haigney
Journal:  Clin J Sport Med       Date:  2007-01       Impact factor: 3.638

2.  Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers.

Authors:  Hein Heidbüchel; Nicole Panhuyzen-Goedkoop; Domenico Corrado; Ellen Hoffmann; Allessandro Biffi; Pietro Delise; Carina Blomstrom-Lundqvist; Luc Vanhees; Per Ivarhoff; Uwe Dorwarth; Antonio Pelliccia
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2006-08

3.  The role of intraventricular conduction disorders in precipitating sudden death.

Authors:  H J Wellens; P Brugada; F W Bär
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

4.  Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

Authors:  Kristian Wachtell; Björn Hornestam; Mika Lehto; David J Slotwiner; Eva Gerdts; Michael H Olsen; Peter Aurup; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Jens Rokkedal; Richard B Devereux
Journal:  J Am Coll Cardiol       Date:  2005-03-01       Impact factor: 24.094

5.  A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study.

Authors:  Tatjana S Potpara; Goran R Stankovic; Branko D Beleslin; Marija M Polovina; Jelena M Marinkovic; Miodrag C Ostojic; Gregory Y H Lip
Journal:  Chest       Date:  2011-05-26       Impact factor: 9.410

6.  Early repolarization pattern in competitive athletes: clinical correlates and the effects of exercise training.

Authors:  Peter A Noseworthy; Rory Weiner; Jonathan Kim; Varsha Keelara; Francis Wang; Brant Berkstresser; Malissa J Wood; Thomas J Wang; Michael H Picard; Adolph M Hutter; Christopher Newton-Cheh; Aaron L Baggish
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-05-04

7.  Prolonged asystolia in a young athlete: a case of sinus arrest during REM sleep.

Authors:  N Sanna; G Della Marca; M Bianco; V Palmieri; A Dello Russo; G Pelargonio; P Zeppilli
Journal:  Int J Sports Med       Date:  2004-08       Impact factor: 3.118

8.  Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists.

Authors:  Sylvette Baldesberger; Urs Bauersfeld; Reto Candinas; Burkhardt Seifert; Michel Zuber; Manfred Ritter; Rolf Jenni; Erwin Oechslin; Pia Luthi; Christop Scharf; Bernhard Marti; Christine H Attenhofer Jost
Journal:  Eur Heart J       Date:  2007-12-07       Impact factor: 29.983

Review 9.  12-lead ECG in the athlete: physiological versus pathological abnormalities.

Authors:  D Corrado; A Biffi; C Basso; A Pelliccia; G Thiene
Journal:  Br J Sports Med       Date:  2009-09       Impact factor: 13.800

10.  The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes.

Authors:  A Pelliccia; B J Maron; A Spataro; M A Proschan; P Spirito
Journal:  N Engl J Med       Date:  1991-01-31       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.